TY  - BOOK
AU  - Kelemen,Kamilla
AU  - Schweizer,P.
AU  - Li,Jin
TI  - Gene therapy for cardiovascular diseases and arrhythmia 
T2  - Cardiology research and clinical developments
SN  - 9781619427549
PY  - 2012///]
CY  - New York
PB  - Nova Biomedical
KW  - Cardiovascular system
KW  - Diseases
KW  - Treatment
KW  - Arrhythmia
KW  - Gene therapy
N1  - Includes index; GENE THERAPY FOR CARDIOVASCULAR DISEASES AND ARRHYTHMIA; GENE THERAPY FOR CARDIOVASCULAR DISEASES AND ARRHYTHMIA; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Introduction; Chapter I: General Principles of Gene Transfer; 1.1. Viral and Non-viral Gene Delivery; 1.2. Adenovirus; 1.3. Adeno-Associated Virus (AAV); 1.4. Retroviruses; 1.5. Lentivirus; 1.6. Naked DNA; References; Chapter II: Gene Delivery Techniques; 2.1. Current Cardiac Gene Delivery Techniques; 2.2. Direct Gene Delivery; 2.3. Intracoronary Infusion; References; Chapter III: Gene Therapy for Coronary Artery and IschemicHeart Disease3.1. Coronary Artery and Ischemic Heart Disease; 3.2. Gene Therapy for Coronary Atherosclerosis; 3.3. Gene Therapy for Angiogenesis in Ischemia; 3.4. Gene Therapy for Myocardial Reperfusion Injury; References; Chapter IV: Gene Therapy for Heart Failure; References; Chapter V: Viral Gene Therapy in Myocarditis; 5.1. Myocarditis, at the Bedside; 5.2. Myocarditis, at the Bench; 5.2.1. Experimental Animal Models and Pathophysiology; 5.2.2. Experimental Viral Myocarditis; 5.2.3. Experimental Autoimmune Myocarditis; 5.2.4. Virus-Associated Gene Transfer5.3. Study Limitations and Open Questions; References; Chapter VI: Gene Therapy for Atrial Arrhythmia: A Therapeutic Approach for Atrial Fibrillation; References; Chapter VII: Gene Therapy for Ventricular Arrhythmia; References; Chapter VIII: Stem Cell Therapy for Cardiovascular Disease; 8.1. Promises and Limitations of Different Cell Populations; 8.1.1. General Aspects; 8.1.2. Differentiation Potential; 8.1.3. Cell Sources in Detail (for Summary Refer to Table 1); 8.1.3.1. Bone Marrow Mononuclear Cells; 8.1.3.2. Mesenchymal Stem Cells; 8.1.3.3. CD133+ Progenitor Cells8.1.3.4. CD34+ Progenitor Cells; 8.1.3.5. Myoblasts; 8.1.3.6. Resident Myocardial Progenitor Cells; 8.1.3.7. Embryonic Stem Cells; 8.1.3.8. Induced Pluripotent Stem Cells; 8.2. Stem Cell Delivery; 8.2.1. Intravenous Administration; 8.2.2. Myocardial Injection; 8.2.3. Intracoronary Delivery; 8.3. Cytokine Therapy; 8.4. Mechanisms of Cell-Based Therapy; 8.4.1. Stem Cell Homing; 8.4.2. Stem Cell Migration within the Myocardium; 8.4.3. Precommitment Versus in Vivo Differentiation; 8.4.4. Transdifferentiation versus Cell Fusion; 8.4.5. Paracrine Effects of Stem Cell Therapy8.5. Stem Cell versus Gene Therapy; 8.6. Future Directions of Cardiovascular Cell-Therapy; 8.6.1. Priming of Stem Cells; 8.6.2. Bionanotechnology to Restore Extracellular Matrix; 8.6.3. Tissue Engineering; References; Chapter IX: Gene Transfer for the Development of a Biological Pacemaker; 9.1. Anatomy and Physiology of the Human Pacemaker; 9.1.1. Anatomic Basis of the Pacemaker; 9.1.2. Differences in the Action Potential between Pacemaker and Non-Pacemaker Cells; 9.1.2.1. Ventricular Myocyte (Non-Pacemaker Cell) Action Potentials
UR  - https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=564942
ER  -